Construction of a recombinant non-pathogenic Leishmania tarentolae expressing Th1 directing chemokine (IP-10)

Immunotherapy which improves the patient's own immune response has been developed in treatment of different cancers as well as leishmaniasis and demonstrated fewer side effects comparing to the conventional therapies. IP-10, a CXC chemokine which produces and strengthens anti-tumor immunity, was applied as an immunotherapy agent. Leishmnia tarentolae (L.tar), a non-pathogenic lizard parasite lacking the ability to persist long time in mammalian macrophages, was applied as live delivery system for carrying immunotherapeutic agent. In this study, IP-10-GFP was transfected to L.tar to produce a proper delivery system for transferring IP-10 to the target organ.

Keywords:

Leishmania tarentolae , IP-10 , pLEXSY plasmid